

## **Technical Bulletin**

## Curian<sup>®</sup> Campy Rapid Fluorescent Immunoassay

TO:	Medical Staff and Clients		
FROM:	Dr. Amy Woron, PhD, MPH, MS V.P Technical Director (Microbiology & Molecular Labs)		
	Tori Enomoto, M(ASCP) Manager, DLS Microbiology	Dr. Wesley Kim, MD Medical Director DLS and QMC West	Dr. Ana Ortega-Lopez, MD Medical Director QMC Punchbowl, North Hawaii and Molokai
DATE:	June 2, 2025		
SUBJECT:	Replacing Campylobacter Culture with Curian <sup>®</sup> Campy		

## Effective Monday, June 2, 2025, the *Campylobacter* component of stool testing will be performed using the Curian<sup>®</sup> Campy rapid fluorescent immunoassay.

As of June 2, Diagnostic Laboratory Services, Inc. (DLS) will begin offering the FDA cleared Curian® Campy rapid fluorescent immunoassay for the detection of a *Campylobacter*-specific antigen in stool specimens, which replaces *Campylobacter* culture in a routine stool culture. Orders for Stool Culture, Unit Code 622, will be redirected to a new Panel Code 8471 that includes the Stool Culture, Shiga Toxin and *Campylobacter* antigen.

*Campylobacter* infection is one of the most widespread infectious diseases and recovery in culture is challenging at best. Culture of *Campylobacter* requires specialized media, a microaerophilic environment, a dedicated incubator set to 42°C and multiple days for biochemical confirmation. The Curian<sup>®</sup> Campy rapid fluorescent immunoassay addresses these culture limitations by offering:

- Same day turn-around-time
- Removes the subjectivity of culture
- Increased sensitivity<sup>1</sup>

Profile code:	UC 8471 (Stool culture, Shiga Toxin and Campy Antigen)
Acceptable Specimen:	Stool (Fecal swab or Cary-Blair)
Optimal Specimen:	Fecal swab, 1 swab; or Cary-Blair
Ambient and Refrigerated Stability:	4 days

<sup>1</sup>Buss JE, Cresse M, Doyle S, Buchan BW, Craft DW, Young S. Campylobacter culture fails to correctly detect Campylobacter in 30% of positive patient stool specimens compared to non-cultural methods. Eur J Clin Microbiol Infect Dis. 2019 Jun;38(6):1087-1093. doi: 10.1007/s10096-019-03499-x. Epub 2019 Feb 19. PMID: 30783889; PMCID: PMC6520473.

Please refer any questions to: Tori Enomoto, Manager, DLS Microbiology at 808-441-5470, or DLS Client Services at 808-589-5101.